Amendment 53
Tilly Metz
on behalf of the Verts/ALE Group
Kateřina Konečná
on behalf of The Left Group

Report
Dolors Montserrat
COVID-19 pandemic: lessons learned and recommendations for the future
(2022/2076(INI))

Motion for a resolution
Paragraph 311

311. Calls on the Commission to publish the non-redacted version of the purchase agreements for the general public after their respective termination dates, including all information of public interest, when legally possible;

311. Calls on the Commission to publish the non-redacted version of the purchase agreements for the general public without further delay;

Or. en
Amendment 54
Tilly Metz
on behalf of the Verts/ALE Group
Kateřina Konečná
on behalf of The Left Group

Report
Dolors Montserrat
COVID-19 pandemic: lessons learned and recommendations for the future
(2022/2076(INI))

Motion for a resolution
Paragraph 549

Motion for a resolution

549. Underlines the benefits of fair and predictable IP protection in fostering and advancing medicinal research, production and development; highlights the public importance of promoting the sharing of IP and know-how of medical countermeasures, in particular during pandemics, epidemics and endemics; stresses that this must not preclude the use of TRIPS flexibility when necessary and as provided by the TRIPS agreement; recognises the importance for the EU to stay in the lead on R&D and clinical trials and underlines the importance of revitalising R&D activities within the EU to create job opportunities and enhance global competitiveness; stresses that intellectual property protection can be an incentive for innovation and research across the globe; notes that such protection can be the basis for voluntary licensing agreements and know-how transfer and can therefore be an enabler of vaccine availability; underlines the challenges that an indefinite TRIPS agreement waiver could pose to research finance, in particular for researchers, investors, developers and clinical trials; emphasises that the protection of property rights, including intellectual property

Amendment

549. Underlines the benefits of fair and predictable IP protection and public funding in fostering and advancing medicinal research, production and development; highlights the public importance of promoting the sharing of IP and know-how of medical countermeasures, in particular during pandemics, epidemics and endemics; stresses that this must not preclude the use of TRIPS flexibility when necessary and as provided by the TRIPS agreement; recognises the importance for the EU to stay in the lead on R&D and clinical trials and underlines the importance of revitalising R&D activities within the EU to create job opportunities and enhance global competitiveness; underlines, in this regard, the importance of transparency and welcomes the Commission’s proposal for a directive relating to medicinal products for human use, which suggests that any direct financial support received from any public authority or publicly funded body in relation to any activities or the research and development of the medicinal product must be declared; highlights the need to both spur innovation and provide access to affordable medicine products; calls for the need to support innovation models that
rights, is a constitutional obligation of the European Union and its Member States; underlines, in this regard, the importance of transparency and welcomes the Commission’s proposal for a directive relating to medicinal products for human use, which suggests that any direct financial support received from any public authority or publicly funded body in relation to any activities or the research and development of the medicinal product must be declared; highlights the need to strike the right balance between spurring innovation and providing access to affordable medicine products; calls for the need to support innovation models that provide access to affordable medicine products in all Member States, without creating serious barriers to access and affordability; calls on the Commission to support global initiatives that facilitate IP sharing such as the COVID-19 technology access pool;
Amendment 55
Tilly Metz
on behalf of the Verts/ALE Group
Kateřina Konečná
on behalf of The Left Group

Report
Dolors Montserrat
COVID-19 pandemic: lessons learned and recommendations for the future
(2022/2076(INI))

Motion for a resolution
Paragraph 550

Motion for a resolution
Amendment

550. Highlights that the existing Agreement on Trade-Related Aspects of Intellectual Property Rights already offers a framework for compulsory licensing, allowing governments to provide their citizens with generic versions of patented treatments through domestic production or foreign imports; acknowledges the potential value of compulsory licensing during pandemics, epidemics and endemics while at the same time recognising its potential negative impacts, such as undermining the certainty of IP protection for future innovation, and highlights the positive role of voluntary licensing agreements in increasing production and access to COVID-19 vaccines, but regrets the limited use of this tool; recalls that 138 voluntary licensing agreements, and partnerships with multilateral organisations, have contributed to worldwide access to COVID-19 therapeutics through means other than TRIPS waivers; urges the Commission and the Member States to prioritise fulfilling the requirement in Article 66(2) of the TRIPS agreement, which mandates developed country members to provide incentives for promoting and encouraging technology transfer to least-developed country members, enabling them to establish a sound and viable technological base;

550. Highlights that the existing Agreement on Trade-Related Aspects of Intellectual Property Rights offers a framework for compulsory licensing, allowing governments to provide their citizens with generic versions of patented treatments through domestic production or foreign imports; acknowledges the potential value of compulsory licensing during pandemics, epidemics and endemics, but regrets that the WTO’s TRIPS waiver that was finalised in the WTO ministerial decision of 17 June 2022 was agreed too late, was not ambitious enough, failed to include therapeutics and diagnostics and therefore failed to improve access conditions to life-saving health technologies in a timely matter to enable global access and curb the Covid-19 pandemic all around the globe; urges the Commission and the Member States to prioritise fulfilling the requirement in Article 66(2) of the TRIPS agreement, which mandates developed country members to provide incentives for promoting and encouraging technology transfer to least-developed country members, enabling them to establish a sound and viable technological base;
transfer to least-developed country members, enabling them to establish a sound and viable technological base;
5.7.2023

Amendment 56
Tilly Metz
on behalf of the Verts/ALE Group

Report
Dolors Montserrat
COVID-19 pandemic: lessons learned and recommendations for the future
(2022/2076(INI))

Motion for a resolution
Paragraph 552

Motion for a resolution

552. **Recalls that** the EU should actively participate in text-based negotiations on a temporary TRIPS waiver; calls, in that regard, for the EU to support the granting of a temporary waiver from certain provisions of the TRIPS agreement for COVID-19, in order to enhance timely global access to affordable COVID-19 vaccines, therapeutics and diagnostics by addressing global production constraints and supply shortages;

Amendment

552. **Calls for** the EU to support text-based negotiations to extend the TRIPS decision agreed at the 12th WTO ministerial conference to therapeutics and diagnostics in order to enhance timely global access to affordable COVID-19 vaccines, therapeutics and diagnostics by addressing global production constraints and supply shortages; **reiterates that in times of crisis, other mechanisms should be used by the EU to enable a global response and crisis mitigation; notes that such mechanisms could, for example, include a Union export control mechanism, enhanced cooperation agreements on the production of medical countermeasures, pre-allocating part of the Union joint procurement, and both voluntary and compulsory technology know-how pools and licensing agreements between companies, which should facilitate people’s access to countermeasures, including people in Eastern Partnership and low- and middle-income countries;**

Or. en
Amendment 57
Tilly Metz
on behalf of the Verts/ALE Group
Kateřina Konečná
on behalf of The Left Group

Report
Dolors Montserrat
COVID-19 pandemic: lessons learned and recommendations for the future
(2022/2076(INI))

Motion for a resolution
Paragraph 553

553. Believes that similar measures would be beneficial in the event of potential future pandemics, epidemics and endemics. Underlines that, in the long term, global production of vaccines must urgently be expanded to meet global demand, and that investment in the production capabilities of low- and middle-income countries is therefore needed to make them more self-sufficient; points out the need for effective transfer of technology and know-how to make this happen; recognises that incentivising voluntary licensing agreements and voluntary technology and know-how transfer to countries with pre-existing vaccine-producing industries should be the most important way to achieve this; considers that a multilateral IPR legal framework can provide protections and incentives which are critical for preparedness against future pandemics and recognises its role in facilitating the broad and unprecedented collaboration among governments, research institutions and pharmaceutical companies;

553. Believes that similar measures would be beneficial in the event of potential future pandemics, epidemics and endemics and supports the inclusion of a TRIPS waiver in the Pandemic Treaty; underlines that, in the long term, global production of vaccines must urgently be expanded to meet global demand, and that investment in the production capabilities of low- and middle-income countries is therefore needed to make them more self-sufficient; points out the need for effective transfer of technology and know-how to make this happen; recognises that incentivising voluntary licensing agreements and voluntary technology and know-how transfer to countries with pre-existing vaccine-producing industries could be a way to achieve this; considers that a multilateral IPR legal framework can provide protections and incentives which are critical for preparedness against future pandemics and recognises its role in facilitating the broad and unprecedented collaboration among governments, research institutions and pharmaceutical companies;

Or. en
5.7.2023

Amendment 58
Tilly Metz
on behalf of the Verts/ALE Group
Kateřina Konečná
on behalf of The Left Group

Report
Dolors Montserrat
COVID-19 pandemic: lessons learned and recommendations for the future
(2022/2076(INI))

Motion for a resolution
Paragraph 585

585. Looks forward to working with the Commission on the revision of the EU general pharmaceuticals legislation, which should continue to adequately protect IP in order to create an innovation-friendly and competitive environment in the Union and to improve equitable access to safe, effective and affordable medicines;

585. deleted

Or. en